FDA OK's J&J's Topamax for adolescent use
This article was originally published in Scrip
Executive Summary
The FDA gave its blessing for Johnson & Johnson subsidiary Janssen to market Topamax (topiramate) as a therapy to prevent migraines in adolescents 12-17 years – making the drug the first product approved as a prophylaxis for the headaches in that population.